Stay updated on Avelumab in Combination with CRT Clinical Trial
Sign up to get notified when there's something new on the Avelumab in Combination with CRT Clinical Trial page.

Latest updates to the Avelumab in Combination with CRT Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a PubMed-based note indicating publications are automatically filled from PubMed, and updated the Revision tag to v3.3.2; removed the older PubMed publication note with v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedAdded the trial site: Tainan, Taiwan, 704. Updated the Tainan address from 'Tainan City, Taiwan, 704' to 'Tainan, Taiwan, 704' and removed a government funding notice.SummaryDifference0.1%

- Check34 days agoChange DetectedThe page content appears unchanged; there are no additions or deletions visible in the screenshots.SummaryDifference0.1%

- Check41 days agoChange DetectedAdded the disease term 'Head and neck squamous cell carcinoma' and a new related topic link 'MedlinePlus Genetics' to the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference1%

- Check70 days agoChange DetectedUpdate terminology to Softer/standardized phrasing: 'Squamous cell carcinoma of the head and neck' replaces 'Head and neck squamous cell carcinoma'; version bumped from v3.0.2 to v3.1.0.SummaryDifference0.2%

Stay in the know with updates to Avelumab in Combination with CRT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avelumab in Combination with CRT Clinical Trial page.